Summary
Pharma innovation leadership: Paola has held progressive innovation leadership roles at Recordati (Director of Innovation, then Vice President Innovation) where she has represented the company in innovation events and led activities within the business development/early investment group focused on external growth. rocketreach+2
Business development and licensing experience: Her career includes multiple business development roles (GSK) and corporate licensing responsibilities at Recordati, indicating experience with deal-making and external innovation sourcing. rocketreach+1
Academic research and technical background: Paola completed doctoral research on CD81 and the immune response and is a co-author on peer-reviewed publications in vaccine and cancer research, reflecting a strong scientific foundation in biotechnology and immunology. depositolegale+2
Engagement with the innovation ecosystem: She participates publicly in innovation-focused events (e.g., Recordati Innovation Day) and panels, signaling active engagement with startups and the digital health community as part of Recordati's innovation outreach. healthverse
Work
Education
Writing
Safety and Immunogenicity of HCV E1E2 Vaccine Adjuvanted with MF59 Administered to Healthy Adults
January 1, 2010Phase I clinical trial report describing safety and immunogenicity of an adjuvanted HCV E1E2 vaccine in healthy adults; Paola Rinella is listed among the authors.
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4
January 1, 2009Research article on mechanisms controlling rhabdomyosarcoma growth and differentiation; Paola Rinella is listed among the authors.
CD81: a paradigm for the modulation of the immune response
Doctoral thesis focused on CD81 and immune response modulation (PhD thesis record).